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ABSTRACT
In melanoma, the adaptative cell response to BRAF inhibitors includes altered 
patterns of cytokine production contributing to tumor progression and drug 
resistance. Among the factors produced by PLX4032-resistant melanoma cell lines, 
CCL2 was higher compared to the sensitive parental cell lines and increased upon 
drug treatment. CCL2 acted as an autocrine growth factor for melanoma cells, 
stimulating the proliferation and resistance to apoptosis. In patients, CCL2 is detected 
in melanoma cells in tumors and in plasma at levels that correlate with tumor burden 
and lactate dehydrogenase. Vemurafenib treatment increased the CCL2 levels in 
plasma, whereas the long-term clinical response was associated with low CCL2 levels.
Increased CCL2 production was associated with miRNA deregulation in the 
resistant cells. miR-34a, miR-100 and miR-125b showed high expression in both 
resistant cells and in tumor biopsies that were obtained from treated patients, and 
they were involved in the control of cell proliferation and apoptosis. Inhibition of CCL2 
and of the selected miRNAs restored both the cell apoptosis and the drug efficacy in 
resistant melanoma cells. Therefore, CCL2 and miRNAs are potential prognostic factors 
and attractive targets for counteracting treatment resistance in metastatic melanoma.
INTRODUCTION
In melanoma cells, the activation of the MAPK 
pathway through BRAF mutations leads to the 
downstream production of several cytokines that promote 
tumor growth, invasiveness and immune evasion through 
their autocrine and paracrine effects [1, 2]. The adaptative 
tumor response to BRAF-targeted drugs that eventually 
leads to the onset of resistance includes increased 
expression of receptor protein kinases and their cytokine 
ligands through autocrine tumor cell production, paracrine 
contribution by the tumor microenvironment or systemic 
production [3–6]. In fact, increased expression of either 
receptor tyrosine kinases, such as PDGFRβ, IGF1R, 
EGFR, MET and ERBB3, and tumor-derived factors 
as IGF1, EGF, NRG and WNT5A has been reported. 
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Moreover, transcription factors including MITF and 
HIF1 has been implicated in BRAF inhibitor (BRAFi) 
responsiveness and resistance [7–9].
Among the cytokines expressed in the tumor 
microenvironment and in the circulation in cancer patients, 
the chemokine monocyte chemoattractant protein-1 (CCL2) 
has been detected in most types of solid cancers [10]. 
Despite its major role in regulating the immune response 
by recruiting monocytes, memory T cells and dendritic 
cells to sites of inflammation, CCL2 also possesses tumor-
promoting potential as demonstrated in several mouse 
models. In fact, the inhibition or neutralization of CCL2 
using drugs or specific antibodies reduced tumor growth 
[11–16]. The tumor-promoting effects of CCL2 have been 
ascribed to the recruitment of monocytes, which leads to a 
profuse vascular network [12]. In line with this hypothesis, 
recent data from clinical trials showed that inhibiting CCL2 
by targeting its receptor or by inhibiting its expression 
effectively reduced tumor-associated macrophages [17]. 
Here, by studying a panel of BRAFV600E melanoma 
cell lines with acquired resistance to BRAFi and plasma 
and tumor samples from vemurafenib-treated melanoma 
patients, we show that the CCL2 production by melanoma 
cells is involved in the resistance to BRAF inhibition and 
that its inhibition may restore drug sensitivity.
Several studies have implicated miRNAs in 
chemoresistance and indicated that they may act through 
interference with drug targets, cell death and angiogenesis 
pathways [18]; however, little is known regarding their 
potential role in melanoma resistance to BRAFi [19, 20]. 
miRNAs are dysregulated in melanoma and are potential 
prognostic markers [21, 22]; in addition, they represent 
potentially druggable targets for treatment strategies. 
Because miRNAs have been involved in the regulation of 
CCL2 secretion [23–25], we explored the role of miRNAs 
in the regulation of BRAFi-resistance. The results showed 
that in association with CCL2 production, a set of 
coordinately regulated miRNAs is induced by BRAFi to 
control melanoma cell apoptosis.
RESULTS
CCL2 is upregulated in PLX4032-resistant 
melanoma cells and reduces BRAFi sensitivity
Melanoma cells are characterized by the expression 
of different cytokines, which may act as potential 
players in reducing the sensitivity to BRAF inhibition. 
Comparison of the secreted proteins between seven 
PLX4032 resistant cell lines and their sensitive parental 
counterparts revealed that the levels of several cytokines 
and chemokines were increased in the resistant cells 
(Supplementary Figure S1). Among them, the chemokine 
CCL2 was significantly upregulated or induced de novo 
at the transcript and protein levels in resistant cell lines 
compared with the matched sensitive cell lines (Figure 
1A), although the cells expressed the CCR2 receptor 
at similar levels (Supplementary Table S1). Because 
the resistant variants were obtained by chronic  in vitro 
exposure to PLX4032, we tested whether drug treatment 
could activate CCL2 production. After exposure to 
PLX4032, both the transcript and the release of CCL2 
were increased in most tested melanoma cell lines (Figure 
1B, Supplementary Table S1).
To investigate the potential autocrine role of CCL2 in 
melanoma cells, the effects of treatment with rCCL2 were 
studied. rCCL2 treatment significantly increased LM16-S cell 
proliferation and decreased drug-induced apoptosis (Figure 
2A). Western blot analysis of the treated cells showed higher 
levels of the Ser473-pAKT and Thr389-pp70S6K kinases, 
indicating that rCCL2 treatment activated the Akt/mTOR 
signaling cascade (Figure 2C). In addition, rCCL2 promoted 
cell migration upon exposure to PLX4032 (Supplementary 
Figure S2A). Similarly, when LM16-S cells were transfected 
with a CCL2 expression plasmid and exposed to BRAFi, 
proliferation increased and cell death was reduced (Figure 
2B). The effect of CCL2 on PLX0342 sensitivity was also 
observed by co-culturing sensitive and resistant cells that were 
physically separated by transwell inserts. In these conditions, 
the anti-proliferative effect of PLX4032 on LM16-S cells 
was reduced, an effect that was abrogated by anti-CCL2 
antibodies (Figure 2D). Inhibiting CCL2 using specific 
siRNAs (siCCL2) reduced the cell viability and increased the 
apoptosis of resistant cell lines (Figure 2E) and prevented cell 
migration (Supplementary Figure S2B). Together, these data 
point to a role of CCL2 in promoting cell survival, migration 
and resistance to BRAFi-induced apoptosis and indicate that 
CCL2 inhibition may enhance drug efficacy.
CCL2 levels are elevated in the tumors and in 
plasma of vemurafenib-treated patients
To assess the potential relevance of CCL2 in disease 
progression and in the response to BRAFi treatment in 
melanoma patients, we studied tumor samples and plasma 
in a set of cases with a follow-up of 2 y after the beginning 
of treatment with vemurafenib [26]. When tumor samples 
were analyzed, the CCL2 gene expression and protein 
levels were higher in five melanoma lesions excised 
during treatment compared with the levels in two biopsies 
that were found to be non-tumoral at histopathology 
examination. The CCL2 levels in the tumors from two 
patients were higher at both a later time of treatment 
(12 vs 2 months) and during treatment compared to pre-
treatment (12 months vs baseline) (Figure 3A). Tissue 
immunostaining showed that six of eight metastatic 
samples obtained during treatment contained CCL2-
positive tumor cells, whereas all samples were stained 
positive for BRAFV600E and contained the mutated 
BRAF gene, as shown by sequence analysis. RNA in situ 
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hybridization confirmed the expression of CCL2 transcript 
in melanoma cells. However, metastatic lesions resected 
before treatment showed a lower frequency of CCL2 
staining (7/18), thus corroborating the evidence of a higher 
CCL2 expression in the treated tumors (Figure 3B and 
Supplementary Table S2).
CCL2 levels quantitatively measured in the plasma 
of patients were significantly higher than those in age- and 
gender-matched healthy donors (HD); in patients, higher 
levels were detected in subjects with a high tumor burden 
than in those with a low tumor burden (Figure 4AB). A 
positive, significant correlation between CCL2 levels and 
the levels of lactate dehydrogenase (LDH) was shown 
(Figure 4C and Supplementary Figure S3A). To analyze 
the potential predictive role of CCL2, we compared long-
term responders (LRs) and short-term responders (SRs) 
with a response lasting at least 2 y for the former and ≤6 
months for the latter. Plasma CCL2 levels were higher in the 
SRs than in the LRs at both baseline and after 1 month of 
therapy (Figure 4D), indicating that high plasma levels are 
Figure 1: CCL2 is upregulated in PLX4032-resistant cell lines and is induced upon drug treatment. A. CCL2 gene 
expression in seven resistant cell lines compared to their sensitive counterparts as detected by quantitative real time RT-PCR and shown as 
2−ΔCt (left); CCL2 release in medium shown as pg/mL/105 cells (right). *p< 0.05 by Mann-Whitney U-test and unpaired t-test. B. Induction 
of CCL2 by short-term (72 h) PLX4032 treatment in resistant and sensitive cell lines, plotted as the fold increase compared to untreated 
controls. S, sensitive cell lines; R, resistant cell lines. *p<0.05, unpaired t-test.
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associated with a lower sensitivity to BRAFi. In ten patients 
treated for 2 y, compared with the pre-treatment levels, the 
CCL2 levels increased significantly after 6 and 12 months of 
treatment with a progressive increase in individual patients 
and without a further significant increase after 2 y (Figure 
4E and Supplementary Figure S3B). Another cytokine, HGF, 
was also measured; HGF levels were higher in patients than 
in HD at the baseline, but in contrast to CCL2, the levels 
of HGF are not associated to tumor burden and showed 
reduction by the treatment (Supplementary Figure S3CDE).
CCL2 expression is associated with increased 
HIF1A and with miR-34a, miR-100 and miR-125b 
upregulation in resistant melanoma cells and in 
the tumors of vemurafenib-treated patients
Among the different molecular pathways that may 
lead to CCL2 production, HIF1A was upregulated in 
LM16-R cells: in fact, the HIF1A gene expression was 
higher than the expression in LM16-S cells, and a variety 
of direct HIF1 target genes, such as EGFR, integrins α1 
Figure 2: CCL2 acts as an autocrine factor for melanoma cells. A. Treatment with rCCL2 (100 ng/mL) increased the number of 
viable LM16-S cells (left) and reduced the number of caspase-3 positive cells upon treatment with PLX4032, as assessed by FACS analysis 
(right). B. pCCL2/LM16-S transfectant cells show an increase in cell growth (left), and a reduction of caspase-3 positive cells after treatment 
with PLX4032 (right) compared to mock transfectants (pmock). pCCL2/LM16-S transfectant cells showed a significant increase in CCL2 
gene expression (137-fold) and protein release (200-fold) when compared to pmock/LM16-S cells. ***p<0.001 and **p<0.01 by two-way 
ANOVA. C. Upregulation of phosphorylated AKT (S473) and p70S6K (T389) in LM16-S cells treated with rCCL2 as detected by western blot 
analysis; vinculin was used as a loading control. D. Proliferation of LM16-S cells in the bottom chamber of transwell plates with LM16-R cells 
loaded into the upper wells; the fold change relative to untreated controls is shown. ***p<0.0001 by one-way ANOVA followed by Bonferroni 
correction. E. Left, transfection with siRNA for CCL2 increases the responsiveness of LM16-R, LM17-R and LM47-R cells to PLX4032 
cell growth inhibition, as detected by MTT assays. Two different siCCL2s (A and B) are shown. The results are shown relative to scrambled 
control. ***p<0.0001 and *p<0.05 by one-way ANOVA followed by Bonferroni correction. Right, PLX4032 treatment increased the number of 
LM16-R, LM17-R and LM47-R cells that were positive for caspase-3 when treated with siRNA for CCL2.
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Figure 3: CCL2 is expressed by melanoma cells in tumor tissues from patients. A. CCL2 gene expression (orange bars) and protein 
(blue bars) detected in fresh surgical melanoma biopsies, including one excised before treatment (A10) and seven during treatment (A2, SE1, SE2, 
B3, and G8), two of which resulting non-tumoral at histopathology (NM1, NM2). A10 and A2 are matched biopsies obtained before and during 
treatment, respectively, whereas SE1 and SE2 are biopsies excised from the same patient at 2 and 12 months of treatment. CCL2 gene expression 
was detected by qRT-PCR and calculated as ∆Ct ± SD relative to β-actin. CCL2 protein was quantified by bead-based FACS analysis: values 
of µg of CCL2 detected in 50 µg of protein lysates are shown. ***p<0.0001 and **p<0.01 by unpaired t-test. B. CCL2 immunostaining of three 
representative tumor lesions showing low (upper), moderate (middle), or high (lower) staining intensity; these lesions were all stained positive 
for BRAFV600E. At the bottom, ISH showing the CCL2-specific signal in the tumor cells (black arrows); UBC staining was used as a control.
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and α5, COX2, and MMP-2/-9 also showed upregulation 
(Figure 5ADE). In addition, HIF1A gene expression was 
decreased by siCCL2 in LM16-R and was increased by 
rCCL2 in LM16-S (Figure 5A). The upregulation of both 
CCL2 and HIF1A upon PLX4032 exposure was significant 
in 6 out of the 12 cell lines tested, including both sensitive 
and resistant cells (Figure 5B). The expression levels of 
CCL2 and HIF1A were positively correlated in BRAF-
mutated melanoma tumor specimens (Figure 5C), further 
supporting an association between HIF1 and CCL2.
Previous studies have reported that miRNA-mediated 
effects could add to the complexity of the molecular 
response orchestrated by the HIF1 transcription factor, 
including the regulation of CCL2 secretion; therefore, 
we evaluated whether miRNAs were involved in the 
CCL2-induced resistance to PLX4032 in melanoma cells. 
A comparison of the miRNA expression profiles of LM16-S 
and LM16-R cells identified 11 differentially expressed 
miRNAs (FDR ≤ 0.05) (Supplementary Figure S4AB). The 
differential expression of seven upregulated miRNAs and 
two of the four downregulated miRNAs was confirmed 
by qRT-PCR analysis in LM16-R cells and in six other 
resistant cell lines (Supplementary Figure S4C and Figure 
6A), indicating a potential association between PLX4032 
resistance and the deregulation of these miRNAs.
miR-34a, miR-100 and miR-125b showed the 
greatest change in expression between the resistant 
variants and the matched parental sensitive cell lines 
and were selected for further study. An analysis of their 
expression in a set of 39 melanoma cell lines confirmed 
their coordinated expression and the association with 
CCL2 (Supplementary Figure S5). In addition, CCL2 
knockdown reduced the expression of miR-34a, miR-100 
and miR-125b in LM16-R cells; conversely, the addition 
of rCCL2 increased their expression in LM16-S cells 
(Figure 6BC). The simultaneous inhibition of miR-34a, 
miR-100 and miR-125b using specific inhibitors reduced 
the CCL2 release, but no effect was observed when 
inhibiting each individual miRNA (Figure 6D).
To determine whether BRAFi treatment increases 
the expression of miR-34a, miR-100 and miR-125b in 
patients, tumors that had been excised for local treatment 
were tested and compared with tumors from untreated 
patients. Higher expression levels of the three miRNAs 
were measured in the samples from the treated patients 
(Figure 7A). In addition, a strong positive correlation 
between the expression of the three miRNAs was shown 
in a set of melanoma specimens (Figure 7B), confirming 
that a common regulatory network integrates their 
expression.
Figure 4: CCL2 plasma levels are high in melanoma patients, depend on tumor burden, and increase during treatment 
with BRAFi. A. CCL2 plasma levels in 32 patients (Pts) and in age-and gender-matched healthy donors (HD). *p<0.05 by unpaired t-test. 
B. Association of CCL2 levels with tumor burden (LTB, low tumor burden; HTB, high tumor burden). ***p<0.0001 by unpaired t-test. C. 
Correlation between plasmatic CCL2 and LDH values. The rs and p values resulting from Spearman analysis are shown. D. Higher CCL2 
levels were found in patients with a short clinical response to treatment (SR, n=23) compared to those in long-term responders (LR, n=10). 
*p<0.05, unpaired t-test; ns, not significant. E. CCL2 levels in LR patients measured at baseline and at different time points during treatment. 
CCL2 plasma levels in two different set of samples from LR patients are shown, LRa (n=10) and LRb (n=12). **p<0.01 by paired t-test.
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Ablation of miR-34a, miR-100 and miR-125b 
restores apoptosis and BRAFi sensitivity
We next examined the potential role of the three 
identified miRNAs in maintaining the viability and 
proliferation of resistant melanoma cells. Although no 
effect were observed in cells treated with inhibitors of one 
or two of the miRNAs, the concomitant inhibition of all 
three miRNAs induced apoptosis and impaired viability 
upon treatment with PLX4032 in LM16-R cells (Figure 
8A) and in other resistant cell lines (Supplementary Figure 
S6). By contrast, the specific miRNA mimics decreased 
BRAFi-induced apoptosis in LM16-S cells (Figure 8B). 
In addition, co-culture assays showed that inhibiting miR-
34a, miR-100 and miR-125b in the LM16-R cells growing 
in the upper chambers reduced the effect of PLX4032 on 
LM16-S cell growth (Figure 8C). The role of the identified 
miRNAs in regulating cell survival was evidenced by 
further testing the effect of manipulating these miRNAs 
on apoptosis: upon exposure to TRAIL, miRNA inhibitors 
increased the fraction of apoptotic cells in LM16-R cells, 
whereas miRNA mimics reduced the number of apoptotic 
LM16-S cells (Figure 8D).
To confirm the involvement of the miRNAs in 
apoptosis, we integrated gene expression data with 
in silico miRNA target prediction. We first identified genes 
targeted by each miRNA using six different algorithms. 
Then, from each list of targets, we selected the genes 
that were downregulated in LM16-R cells that were also 
included in canonical apoptotic pathways in the MsigDB 
database [27]. Interestingly, for each miRNA, a set of 
strongly downregulated, apoptosis-related targets was 
identified (Supplementary Table S3). Overall, these results 
support the roles of miR-34, miR-100, and miR-125b in 
promoting the survival of resistant cells by negatively 
regulating apoptotic genes.
Figure 5: Concerted HIF1A and CCL2 regulation. A. HIF1A gene expression analysis showing upregulation in LM16-R cells 
compared to LM16-S cells, reduction upon CCL2 silencing (siCCL2), and an increase in LM16-S cells treated with rCCL2 at 100 ng/mL 
for 24 h. Actin was used as the internal reference and LM16-S or siControl as the calibrator. Relative quantification (RQ) values obtained 
by qRT-PCR are shown. ***p<0.0001 and *p<0.05 by unpaired t-test. B. Increase in HIF1A gene expression in melanoma cell lines upon 
PLX4032 treatment. 2−ΔCt values are shown. *p<0.05 by Mann-Whitney U-test. C. Analysis of the correlation between the CCL2 and HIF1A 
gene expression levels in melanoma tissues from patients (n=20). The rs and p values resulting from Spearman analysis are shown. D. 
Expression levels of HIF1 targets in LM16-R compared to LM16-S cell lines. FACS analysis detection of EGFR, integrin α1 and integrin 
α5. Percentages of protein expression are shown in the graph. E. Expression of COX2 in LM16-S and LM16-R cells as detected by western 
blot analysis; production of MMP-2/-9 as detected by gelatin zymography in supernatants from LM16-S and LM16-R cells.
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DISCUSSION
This study shows that drug treatment induces CCL2 
production in melanoma cells and that CCL2 acts as an 
autocrine growth factor that promotes cell survival and 
apoptosis resistance. Most importantly, targeting CCL2 
has the potential to enhance the effect of the drug. CCL2 
is detectable in several types of tumors [10] and was 
previously detected in human melanoma cell lines [28], 
but CCL2 was not previously reported in melanoma cells 
from tumor specimens. High serum CCL2 levels are part of 
the disease-induced systemic alterations that are correlated 
with a poor prognosis in breast, pancreatic and lung cancers 
[29–31]. Our results show that also melanoma patients 
display high CCL2 levels in the plasma, and these levels are 
correlated with tumor burden and LDH levels. In agreement 
with a tumor-promoting role, higher CCL2 plasma levels 
after one month of therapy were detected in patients with 
short-term responses to BRAFi treatment compared with 
the levels in long-term responders. This pattern was only 
partially related to the LDH and tumor burden levels, as the 
baseline LDH levels were not significantly different between 
LR and SR patients, and not all LR patients had a low tumor 
burden. Our data confirm the results of Wilmott et al. [32], 
who showed that high serum CCL2 levels were associated 
with a poor clinical response at two months of treatment. 
Furthermore, our results showed a slight but significant 
increase in plasma CCL2 levels in patients receiving drug 
treatment for a long-term period; this finding suggests that 
although the treatment increases the plasma levels, the 
magnitude of the increase is associated with response to 
the treatment, possibly reflecting treatment-induced CCL2 
production in the tumor. The CCL2 expression was higher 
in the tumor tissues from treated patients, thus supporting 
Figure 6: miR-34a, miR-100 and miR-125b are upregulated in resistant cells. A. Expression levels of selected miRNAs in 
seven resistant cell lines relative to that in their sensitive counterparts. 2−ΔCt values calculated relative to U6 used as the internal reference 
are shown. *p<0.05, **p<0.01 by Mann-Whitney U-test. B. In LM16-R cells, silencing of CCL2 reduces the expression of miR-34a, miR-
100 and miR-125b. miRNA expression is shown as RQ values calculated by comparison to the scrambled control. *p<0.05 and ***p<0.0001 
by unpaired t-test. C. In LM16-S cells, treatment with rCCL2 increased the expression of miR-34a, miR-100 and miR-125b. rCCL2 was 
used at 100 ng/mL for 72 h. miRNA expression is shown as RQ values calculated by comparison to untreated cell control. ***p<0.0001 by 
unpaired t-test. D. Reduction of CCL2 release by LM16-R cells after inhibition of miR-34a, miR-100 and miR-125b in combination but 
not when each was individually inhibited. Data are presented as the percent change when compared to the scrambled control.***p<0.0001 
by one-way ANOVA followed by Bonferroni correction. i-miR, specific miRNA inhibitors.
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Figure 8: Inhibition of miR-34a, miR-100 and miR-125b increases responsiveness to PLX4032. A. Concomitant inhibition 
of miR-34a, miR-100 and miR-125b increased the antiproliferative effect of BRAFi treatment as indicated by MTT assay (left) and increased 
caspase-3 positive cells (right). ***p<0.0001 by unpaired t-test. The expression of miR-34a, miR-100 and miR-125b was reduced by 3.3-, 
100-, and 25-fold, respectively. B. The increased expression of miR-34a, miR-100 and miR-125b caused by the transfer of miRNA mimics 
reduced the apoptosis in LM16-S cells. The expression of miR-34a, miR-100 and miR-125b was increased by 14200-, 4227- and 812-fold, 
respectively. C. Left, LM16-S cell growth in transwell plates shown as the fold change compared to the untreated control: co-culture with 
LM16-R cells in the upper chamber reduced the antiproliferative effect of PLX4032. Right, the inhibition of miR-34a, miR-100 and miR-
125b by specific miRNA inhibitors (i-miR) increases the antiproliferative effect of the drug. Fold change values compared to scrambled 
control are shown. ***p<0.0001 by one-way ANOVA followed by Bonferroni correction, *p<0.05 by unpaired t-test. Microscope appearance 
of the co-cultured cells (magnification 10X). D. Cell apoptosis induced by soluble TRAIL (50 ng/mL for 24 h) after the treatment with 
inhibitors (i-miR) or mimics (m-miR) of miR-34a, miR-100 and miR-125b. The fraction of activated caspase-3-positive cells is shown.
Figure 7: miR-34a, -100 and -125b are upregulated in tumors from patients treated with BRAFi. A. Expression levels 
of miR-34a, miR-100 and miR-125b in metastatic lesions excised from patients during treatment with BRAFi (n=5) (treated) and before 
treatment (n=20) (untreated). **p<0.01, ***p<0.0001 by Mann-Whitney U-test. B. Analysis of the correlation between miR-125b expression 
and the expression of miR-34a and miR-100 in BRAFV600E melanoma tissues (n=27). The rs and p values resulting from Spearman 
analysis are shown.
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an in vivo induction in melanoma cells by drug treatment. 
Immunostaining revealed that tumor cells were the main 
cellular source of CCL2, whereas a minor amount of 
staining was due to immune infiltrate (not shown). More 
samples are required to determine whether it is possible to 
define a threshold level of CCL2 in plasma for predicting 
the patient response to treatment.
CCL2 is induced by reactive oxygen driven 
pathways, pro-inflammatory cytokines and growth factors 
via NF-kB signaling and HIF1 transcriptional control [33, 
34]. CCL2 is not only directly upregulated by hypoxia-
induced transcription but also able to induce a hypoxic 
response that results in the upregulation of a variety of 
HIF1 direct target genes [35, 36]. The inhibition of reactive 
oxygen pathways by small molecules reduces the release 
of cytokines, including CCL2 [37]. miRNAs have been 
reported to regulate the HIF1 response and CCL2 secretion 
[23–25]. We found miR-34a, miR-100 and miR-125b 
were upregulated by CCL2 and were directly involved in 
BRAFi resistance. In fact, miR-34a, miR-100 and miR-
125b were coordinately increased in seven resistant cell 
lines and overexpressed in the tumor biopsies obtained from 
patients undergoing vemurafenib treatment. Ablating the 
three miRNAs restored sensitivity to BRAFi by increasing 
apoptosis, suggesting that miRNA inhibitors may increase 
the effect of BRAFi therapy (Figure 9). Interestingly, two 
of the identified miRNA genes, MIR100 and MIR125B1, 
cluster at intron 3 of the MIR100HG lncRNA gene at the 
11q24.1 region (UCSC Genome Browser Human Feb. 
2009 GRCh37/hg19 Assembly). In agreement with their 
coordinated transcription, the expression levels of miR-
125b and miR-100 were significantly correlated in both 
cell lines and tumor biopsies. We showed the involvement 
of miR-34a, miR-100 and miR-125b in TRAIL-induced 
apoptosis, a finding that has potential implications for tumor 
cells killing by immune cytotoxic effectors. Consistent 
with our results, miR-125b, miR-34a and miR-100 were 
previously shown to be involved in chemoresistance in 
several cancer types through downregulation of key pro-
apoptotic genes [38–41].
In conclusion, our results indicate that CCL2 and 
miR-125b, miR-34a and miR-100 are potential targets for 
overcoming the resistance to BRAFi in melanoma.
MATERIALS AND METHODS
Melanoma cell cultures and in vitro assays
The melanoma cell lines used in this study were 
described previously [42]. The PLX4032-resistant cell 
line variants were generated by repeated exposure until the 
onset of resistance (Supplementary Table S1) as previously 
described [43]. PLX4032 (Active Biochem) was used at a 
concentration of 3 µM unless otherwise indicated.
MTT colorimetric assays were used to determine cell 
viability [43]. Co-cultures were set in transwell chambers 
with 24-well inserts with a pore size of 0.4 µm (Corning 
Costar). Cell apoptosis was detected using a Caspase-3 
Apoptosis Kit (Becton Dickinson) by flow cytometry with 
a FACScan instrument (Becton Dickinson). Scratch wound 
assays were performed on confluent cell monolayers in 
six-well plates: the monolayer was scratched using a 
sterile pipette tip, rinsed to remove detached cells, and 
treated with inhibitors for 72 h.
Multiple analyte bead-based FlowCytomixTM 
arrays were used to quantify CCL2 and other cytokines 
in the medium and in plasma using Pro 2.4 software 
(eBioscience). A human cytokine antibody array (AAH-
CHE-1, Ray Biotech Inc.) was used to detect cytokine 
levels.
Matrix metalloproteinase 2 and 9 (MMP-2/-9) 
activity was assessed using 10% SDS-PAGE gelatin 
substrate zymography in serum-free conditioned medium 
after sample concentration with an Amicon Ultra 10K.
The following antibodies were used: anti-phospho-
AKT S473 (4051; Cell Signaling); anti-vinculin (V9131; 
Sigma); anti-COX2 (sc-1745; Santa Cruz); anti-p70S6 
kinase (05-781) and anti-phospho(T389)-p70S6 kinase 
(04-392) from Upstate Biotechnology; anti-AKT 
(610861), anti—EGFR (555997) and anti-CCR2 (558406) 
Figure 9: Schematic representation of the CCL2/HIF1/miRNA loop associated with resistance. In resistant cells, CCL2 
production is associated with HIF1 activation and miR-34a, miR-100 and miR-125b upregulation. The inhibition of CCL2 or of miRNAs 
restores PLX4032 responsiveness. siCCL2, CCL2 siRNA; i-miR, miRNA inhibitors.
Oncotarget4438www.impactjournals.com/oncotarget
from Becton Dickinson; anti-α1-integrin (MAB19737) 
and anti-α5-integrin (MAB1999) from Chemicon.
For the generation of stable transfectants expressing 
CCL2, human CCL2 cDNA was cloned from pDONR223-
CCL2 (#23552, Addgene) into a pcDNA3.1/HisC 
plasmid vector; CCL2/LM16-S and empty plasmid 
control transfectants were selected in G418 (Invitrogen). 
Recombinant human CCL2 (Peprotech) and neutralizing 
anti-CCL2 antibody (MAB279, R&D System) were used 
at 100 ng/mL and 5 µg/mL, respectively. Soluble TRAIL 
was used at 50 ng/mL (Adipogen).
Transient transfections were carried out by using 
Metafectene (Biontex) or Lipofectamine 2000 (Invitrogen). 
CCL2 was silenced using small interfering RNA 
(siCCL2-A, GCAAGUGUCCCAAAGAAGC; siCCL2-B, 
CCCAAACUCCGAAGACUUG), and a scrambled control 
(D-001810-10, Dharmacon) was used in these experiments.
miR-34a, miR-100 and miR-125b were knocked 
down using miRNA inhibitors (AM11030, AM18188, 
AM10148) and were overexpressed using miRNA mimics 
(PM11030, MC10188, MC10148); scrambled mimic/
inhibitor controls (AM17010 and 4464058) were used 
(Ambion).
Microarray profiling
For gene expression profiling, HumanHT-12 v4 
Illumina microarrays were scanned with an Illumina 
BeadArray Reader, and raw data obtained using Illumina 
BeadStudio v3.3.8 were processed using the lumi package 
[44] from Bioconductor [45]. Raw data were log2-
transformed, normalized using robust spline normalization 
and filtered; only the probes with a detection p-value <0.01 
in at least one sample were further analyzed. Multiple 
probes representing the same gene were collapsed, and 
the probe with the highest detection rate was selected. 
In the case of equal detection rates, the probe with the 
greatest variation, as indicated by the interquartile range, 
was selected. For microRNA profiling, Human miRNA 
miRBase 16 microarrays from Agilent were scanned with 
an Agilent SureScan scanner, and raw data were collected 
using Agilent’s Feature Extraction software v10.7. Raw 
data were preprocessed using an optimized version of the 
RMA algorithm implemented in the AgiMicroRna package 
[46]. miRNAs that were detected in at least one sample, 
as indicated by the gIsGeneDetected information given 
by the Feature Extraction software, were kept for further 
analyses. Genes and miRNAs that were differentially 
expressed between LM16-R and LM16-S cells were 
identified using the limma package. Multiple-testing 
correction was performed using the Benjamini-Hochberg 
false discovery rate (FDR). Genes with FDR <0.05 and 
absolute fold-change ≥ 2 and miRNAs with FDR <0.05 
and absolute fold-change ≥1.5 were considered significant. 
The data were deposited in the GEO repository (accession 
number GSE68841).
In silico miRNA target prediction
In silico prediction of miRNA targets was performed 
simultaneously using 6 algorithms: DIANA MicroT-CDS 
[47], microRNA.org database [48], mirDB [49], PITA [50], 
RNA22 [51], and TargetScan v6.2 [52]. Targets that were 
predicted by at least one algorithm and that were significantly 
changed in the opposite manner of the selected miRNAs were 
then compared with the list of genes involved in apoptosis. 
Apoptotic genes were derived from 48 canonical pathways 
(c2.cp.v4.0 collection) retrieved from the MSigDB database 
[subramanian] by searching for the keyword “apoptosis”.
Clinical samples
Blood samples were collected at different time points 
from one stage IIIC and 31 stage IV melanoma patients who 
were consecutively enrolled for treatment with vemurafenib 
from Oct 2011 to Feb 2012. Plasma was immediately 
separated from blood cells by centrifugation at 1700 g for 
15 min. The 10 female and 22 male patients were aged 32-
73 y; seven had M1a disease, ten had M1b disease, and 
fourteen had M1c disease. The tumor burden was defined 
based on the tumor volume (calculated as the sum of all 
index lesions >10x10 mm) and the extent of the disease: a 
low tumor burden was defined as nodal disease (N) and/or 1 
extranodal (EN) site, and a high tumor burden was defined 
as ≥2 EN sites ±N. Short-term responses (≤6-9 months) and 
long-term responses (≥24 months) were defined based on 
periodic clinical evaluations during treatment. A second set of 
plasma samples was obtained from twelve patients who were 
treated for 20-39 months; the samples were from 5 female 
and 7 male patients aged 38-72 y, three of whom were at 
stage IIIC, and nine were at stage IV (4 M1a, 2 M1b and 3 
M1c). Control plasma from age- and gender-matched healthy 
blood donors was obtained from the Immunohematology 
Service. Fresh tumor samples that had been excised for local 
treatment in patients undergoing therapy were obtained from 
the Pathology Unit and snap frozen in liquid nitrogen. The 
study was approved by the Institutional Review Board and 
by an Independent Ethics Committee, and patient and healthy 
donor samples were included upon informed consent.
Immunostaining and in situ hybridization (ISH)
Antigen retrieval was performed by heating in 
a pressure cooker in 5 mM citrate buffer solution or in 
5 mM EDTA pH 8 for 15 min, followed by cooling for 
15 min prior to immunostaining for CCL2 (20530002, 
Novus Biologicals) or BRAF (VE1, Spring Bioscience), 
respectively. ISH was performed by hybridization for 3 
h at 40°C. After probe amplification, the CCL2 probe 
(VA1-11041-01, eBioscience) was detected using an 
alkaline phosphatase-conjugated probe, and the product 
was developed using Fast Red substrate, whereas the UBC 
probe was examined using Fast Blue substrate.
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Real-time reverse transcription-PCR analysis 
(qRT-PCR)
The reactions were performed in triplicate on an 
ABI PRISM 7900 real-time sequence detection system 
(Life Technologies). The results are presented as relative 
quantification (RQ) and are calculated as RQ=(2−ΔΔCt) ± 
RQ min/max when using the control samples as calibrators 
or as 2−ΔCt ± SD for direct comparisons. miRVANA 
(Ambion) and a High-Capacity cDNA Archive kit (Life 
Technologies) or Mircury LNA Universal RT microRNA 
PCR universal cDNA synthesis kit II (Exiqon) were used 
for RNA extraction and retrotranscription. TaqMan assays 
for CCL2 (Hs00234140_m1), HIF1A (Hs00153153_m1) 
and β-actin (4326315E) were used, and Exiqon reagents 
were used for miRNA amplifications.
Statistical analysis
Statistical analyses were performed using Prism 
software v.5. Comparisons between continuous variables 
in two groups were performed using an unpaired two-
tailed Student’s t-test or, in the case of paired samples, 
a paired two-tailed Student’s t-test. For the 2-ΔCT qRT-
PCR data, the non-parametric Mann-Whitney U-test was 
used. For comparisons involving more than two groups, 
one-way ANOVA was used, followed by Bonferroni 
correction. For comparisons between two time-course or 
dose-response curves, two-way ANOVA was used. The 
correlation between linear variables was calculated using 
Pearson or Spearman’s correlation coefficients.
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